Emerging Markets Drive Consumer Health Growth, Pose Challenges
This article was originally published in PharmAsia News
Executive Summary
Developing markets account for 50% of the global self-care product sales, but close to 100% of the sector’s growth, according to market research firm IMS Health. This picture will continue as OTC drugs and dietary supplements have a bigger health care role in developing countries than in developed markets.
You may also be interested in...
GSK Hones OTCs As “Sharp End” Of Consumer Products Business
Glaxo’s OTC business is “the very best end of consumer goods as opposed to being a poor relation of pharmaceuticals,” says Emma Walmsley, GSK Consumer Healthcare president.
Oxytrol For Women Gets OTC Green Light As Rare First-In-Class Switch
FDA approved Merck’s overactive bladder drug Oxytrol for Women for OTC use, despite concerns raised by the Nonprescription Drug Advisory Committee in November. The company plans a launch in the fall.
Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
Sanofi-Aventis will launch nonprescription Allegra allergy relief products March 4, but the line might not beat private-label fexofenadine products to store shelves.